A Phase II, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Adaptive Dose-ranging Study to Evaluate the Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis

Trial Profile

A Phase II, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Adaptive Dose-ranging Study to Evaluate the Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis

Discontinued
Phase of Trial: Phase II

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs Secukinumab (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 14 May 2015 According to the ClinicalTrials.gov record, status changed from completed to discontinued.
    • 01 Aug 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 13 Jul 2013 New source identified and integrated (European Clinical Trials Database; EudraCT2012-004019-29).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top